{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T16:47:07Z","timestamp":1789922827367,"version":"4.0.1"},"reference-count":49,"publisher":"Impact Journals, LLC","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2014,10,15]]},"DOI":"10.18632\/oncotarget.2361","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T23:37:56Z","timestamp":1442360276000},"page":"9118-9132","source":"Crossref","is-referenced-by-count":75,"title":["Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr\/Abl-dependent and -independent mechanisms"],"prefix":"10.18632","volume":"5","author":[{"given":"Xin","family":"Chen","sequence":"first","affiliation":[{"name":"State Key Lab of Respiratory Disease, Protein Modification and Degradation Lab, Departments of Pathophysiology and Biochemistry, Guangzhou Medical University, Guangdong 510182, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianping","family":"Shi","sequence":"additional","affiliation":[{"name":"State Key Lab of Respiratory Disease, Protein Modification and Degradation Lab, Departments of Pathophysiology and Biochemistry, Guangzhou Medical University, Guangdong 510182, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Zhao","sequence":"additional","affiliation":[{"name":"State Key Lab of Respiratory Disease, Protein Modification and Degradation Lab, Departments of Pathophysiology and Biochemistry, Guangzhou Medical University, Guangdong 510182, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofen","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Lab of Respiratory Disease, Protein Modification and Degradation Lab, Departments of Pathophysiology and Biochemistry, Guangzhou Medical University, Guangdong 510182, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Lan","sequence":"additional","affiliation":[{"name":"State Key Lab of Respiratory Disease, Protein Modification and Degradation Lab, Departments of Pathophysiology and Biochemistry, Guangzhou Medical University, Guangdong 510182, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouting","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Lab of Respiratory Disease, Protein Modification and Degradation Lab, Departments of Pathophysiology and Biochemistry, Guangzhou Medical University, Guangdong 510182, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbiao","family":"Huang","sequence":"additional","affiliation":[{"name":"State Key Lab of Respiratory Disease, Protein Modification and Degradation Lab, Departments of Pathophysiology and Biochemistry, Guangzhou Medical University, Guangdong 510182, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Lab of Respiratory Disease, Protein Modification and Degradation Lab, Departments of Pathophysiology and Biochemistry, Guangzhou Medical University, Guangdong 510182, China"},{"name":"Guangzhou Research Institute of Cardiovascular Disease, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510260, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyan","family":"Liao","sequence":"additional","affiliation":[{"name":"State Key Lab of Respiratory Disease, Protein Modification and Degradation Lab, Departments of Pathophysiology and Biochemistry, Guangzhou Medical University, Guangdong 510182, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zang","sequence":"additional","affiliation":[{"name":"State Key Lab of Respiratory Disease, Protein Modification and Degradation Lab, Departments of Pathophysiology and Biochemistry, Guangzhou Medical University, Guangdong 510182, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Song","sequence":"additional","affiliation":[{"name":"State Key Lab of Respiratory Disease, Protein Modification and Degradation Lab, Departments of Pathophysiology and Biochemistry, Guangzhou Medical University, Guangdong 510182, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Liu","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing Z.","family":"Carter","sequence":"additional","affiliation":[{"name":"Section of Molecular Hematology and Therapy, Department of leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q. Ping","family":"Dou","sequence":"additional","affiliation":[{"name":"State Key Lab of Respiratory Disease, Protein Modification and Degradation Lab, Departments of Pathophysiology and Biochemistry, Guangzhou Medical University, Guangdong 510182, China"},{"name":"The Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, and Departments of Oncology, Pharmacology and Pathology, School of Medicine, Wayne State University, Detroit, Michigan 48201-2013, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Lab of Respiratory Disease, Protein Modification and Degradation Lab, Departments of Pathophysiology and Biochemistry, Guangzhou Medical University, Guangdong 510182, China"},{"name":"Division of Basic Biomedical Sciences, Sanford School of Medicine of the University of South Dakota, Vermillion, South Dakota 57069, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbao","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Lab of Respiratory Disease, Protein Modification and Degradation Lab, Departments of Pathophysiology and Biochemistry, Guangzhou Medical University, Guangdong 510182, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2014,8,22]]},"reference":[{"issue":"3","key":"1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"4946","key":"2","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","article-title":"Tyrosine kinase activity and transformation potency of bcr-abl oncogene products","volume":"247","author":"Witte","year":"1990","journal-title":"Science"},{"issue":"50","key":"3","doi-asserted-by":"crossref","first-page":"39223","DOI":"10.1074\/jbc.M007291200","article-title":"BCR\/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase\/AKT pathway","volume":"275","author":"Griffin","year":"2000","journal-title":"J Biol Chem"},{"issue":"21","key":"4","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1038\/sj.onc.1203484","article-title":"JAK-STAT signaling activated by Abl oncogenes","volume":"19","author":"Rothman","year":"2000","journal-title":"Oncogene"},{"issue":"11","key":"5","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/sj.onc.1201664","article-title":"Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL","volume":"16","author":"Green","year":"1998","journal-title":"Oncogene"},{"issue":"7","key":"6","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/leu.2012.19","article-title":"Gfi-1 inhibits proliferation and colony formation of p210BCR\/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1","volume":"26","author":"Calabretta","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"7","first-page":"e2","article-title":"ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(\u2212) population to imatinib","volume":"40","author":"Belloc","year":"2012","journal-title":"Exp Hematol"},{"issue":"9","key":"8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1358\/dot.2012.48.9.1869590","article-title":"New and established tyrosine kinase inhibitors for chronic myeloid leukemia","volume":"48","author":"Bowles","year":"2012","journal-title":"Drugs Today (Barc)"},{"issue":"29","key":"9","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.2174\/092986708786848578","article-title":"Targeted drugs in chronic myeloid leukemia","volume":"15","author":"Robak","year":"2008","journal-title":"Curr Med Chem"},{"issue":"16","key":"10","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.24418","article-title":"Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase","volume":"115","author":"Cortes","year":"2009","journal-title":"Cancer"},{"issue":"12","key":"11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"Cortes","year":"2006","journal-title":"Ann Intern Med"},{"issue":"1","key":"12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/asheducation-2005.1.183","article-title":"Loss of response to imatinib: mechanisms and management","volume":"2005","author":"Shah","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"13","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/1078-0432.CCR-08-2141","article-title":"Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation","volume":"15","author":"Pan","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"10","key":"14","first-page":"67","article-title":"Nilotinib treatment in mouse models of P190 Bcr\/Abl lymphoblastic leukemia","volume":"6","author":"Heisterkamp","year":"2007","journal-title":"Mol Cancer"},{"issue":"24","key":"15","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Sawyers","year":"2006","journal-title":"N Engl J Med"},{"issue":"11","key":"16","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1002\/ijc.23435","article-title":"Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl\/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification","volume":"122","author":"Ueda","year":"2008","journal-title":"Int J Cancer"},{"issue":"19","key":"17","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Kantarjian","year":"2013","journal-title":"N Engl J Med"},{"issue":"9","key":"18","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1021\/cr980431o","article-title":"Gold-based therapeutic agents","volume":"99","author":"Shaw","year":"1999","journal-title":"Chem Rev"},{"issue":"5","key":"19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2131\/jts.36.635","article-title":"Auranofin protects against cocaine-induced hepatic injury through induction of heme oxygenase-1","volume":"36","author":"Yoshida","year":"2011","journal-title":"J Toxicol Sci"},{"issue":"9","key":"20","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1158\/0008-5472.CAN-13-2033","article-title":"Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia","volume":"74","author":"Bhalla","year":"2014","journal-title":"Cancer Res"},{"issue":"4","key":"21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/sj.bjp.0705708","article-title":"Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro","volume":"142","author":"Park","year":"2004","journal-title":"Br J Pharmacol"},{"issue":"9","key":"22","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1039\/c1mt00062d","article-title":"Gold compounds as therapeutic agents for human diseases","volume":"3","author":"Filipovska","year":"2011","journal-title":"Metallomics"},{"issue":"6","key":"23","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.freeradbiomed.2006.12.021","article-title":"Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells","volume":"42","author":"Rigobello","year":"2007","journal-title":"Free Radic Biol Med"},{"issue":"8","key":"24","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/rheumatology\/36.8.870","article-title":"Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis","volume":"36","author":"Brodin","year":"1997","journal-title":"Br J Rheumatol"},{"issue":"6","key":"25","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nm.2758","article-title":"A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target","volume":"18","author":"Reed","year":"2012","journal-title":"Nat Med"},{"key":"26","article-title":"Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth","author":"Liu","year":"2014","journal-title":"Oncotarget"},{"issue":"8","key":"27","first-page":"853","article-title":"The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr\/Abl-positive cell lines sensitive and resistant to imatinib mesylate","volume":"88","author":"Beran","year":"2003","journal-title":"Haematologica"},{"issue":"1","key":"28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/1078-0432.CCR-13-1063","article-title":"Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation","volume":"20","author":"Liu","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"3","key":"29","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2141.2002.03468.x","article-title":"p53 expression in K562 cells is associated with caspase-mediated cleavage of c-ABL and BCR-ABL protein kinases","volume":"117","author":"Cotter","year":"2002","journal-title":"Br J Haematol"},{"issue":"5","key":"30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.tiv.2005.11.001","article-title":"Gold-induced reactive oxygen species (ROS) do not mediate suppression of monocytic mitochondrial or secretory function","volume":"20","author":"Wataha","year":"2006","journal-title":"Toxicol In Vitro"},{"issue":"3","key":"31","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.bbrc.2008.02.006","article-title":"Thioredoxin reductase-1 knock down does not result in thioredoxin-1 oxidation","volume":"368","author":"Spielberger","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"32","first-page":"1179","article-title":"BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death","volume":"83","author":"Cotter","year":"1994","journal-title":"Blood"},{"issue":"17","key":"33","first-page":"1673","article-title":"Second-generation BCR-ABL kinase inhibitors in CML","volume":"363","author":"Haznedaroglu","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"34","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/jm301581y","article-title":"Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib","volume":"56","author":"Ding","year":"2013","journal-title":"J Med Chem"},{"issue":"3","key":"35","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1182\/blood.V86.3.1148.1148","article-title":"BCR-ABL-mediated inhibition of apoptosis with delay of G2\/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents","volume":"86","author":"Jones","year":"1995","journal-title":"Blood"},{"issue":"5","key":"36","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.cdd.4401210","article-title":"Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity","volume":"10","author":"Amarante-Mendes","year":"2003","journal-title":"Cell Death Differ"},{"issue":"6","key":"37","first-page":"440","article-title":"Inhibition of thioredoxin reductase by auranofin induces apoptosis in adriamycin-resistant human K562 chronic myeloid leukemia cells","volume":"66","author":"Gao","year":"2011","journal-title":"Pharmazie"},{"issue":"6","key":"38","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.bcp.2003.10.031","article-title":"Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells","volume":"67","author":"Dou","year":"2004","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"39","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","article-title":"The development of proteasome inhibitors as anticancer drugs","volume":"5","author":"Adams","year":"2004","journal-title":"Cancer cell"},{"issue":"12","key":"40","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia","volume":"117","author":"Sexl","year":"2011","journal-title":"Blood"},{"issue":"12","key":"41","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","article-title":"The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors","volume":"117","author":"Frank","year":"2011","journal-title":"Blood"},{"issue":"22","key":"42","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1038\/onc.2010.81","article-title":"Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells","volume":"29","author":"Perez-Roger","year":"2010","journal-title":"Oncogene"},{"issue":"4","key":"43","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.clml.2011.06.004","article-title":"Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase","volume":"11","author":"Cortes","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5483\/BMBRep.2013.46.1.123","article-title":"Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells","volume":"46","author":"Kim","year":"2013","journal-title":"BMB Rep"},{"issue":"6","key":"45","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1039\/c2ja30109a","article-title":"Speciation analysis of the antirheumatic agent Auranofin and its thiol adducts by LC\/ESI-MS and LC\/ICP-MS","volume":"27","author":"Karst","year":"2012","journal-title":"J Anal At Spectrom"},{"issue":"3","key":"46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0167-7799(03)00004-0","article-title":"A new science-business paradigm in anticancer drug development","volume":"21","author":"Blagosklonny","year":"2003","journal-title":"Trends Biotechnol"},{"issue":"5","key":"47","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.bmc.2010.01.052","article-title":"Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl","volume":"18","author":"Pan","year":"2010","journal-title":"Bioorg Med Chem"},{"issue":"12","key":"48","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/cr.2010.123","article-title":"Physiological levels of ATP negatively regulate proteasome function","volume":"20","author":"Liu","year":"2010","journal-title":"Cell Res"},{"issue":"11","key":"49","doi-asserted-by":"crossref","first-page":"e49062","DOI":"10.1371\/journal.pone.0049062","article-title":"L-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro","volume":"7","author":"Liu","year":"2012","journal-title":"PLoS One"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2361","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T04:35:05Z","timestamp":1691987705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.2361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,22]]},"references-count":49,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2014,10,15]]}},"alternative-id":["2361","25193854"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.2361","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,22]]}}}